Figure 2.

Change in monthly headache days, monthly migraine days, acute medication use, and Headache Impact Test-6 (HIT-6) score from baseline to weeks 9–12 of erenumab use in men and women. Each dot represents a patient. Blue dots indicate men, while red dots indicate women.